Mesa Laboratories Inc (MLAB)
212.06
-0.11 (-0.05%)
USD |
NASDAQ |
May 20, 16:00
212.08
+0.02 (+0.01%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.112B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.27% |
| Valuation | |
| PE Ratio | 148.29 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.010 |
| Price to Book Value | 2.807 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.16 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5782 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 35.69% |
News
Headline
Wire
Time (ET)
Yahoo
05/13 10:17
Yahoo
04/12 09:51
MT Newswires
04/06 13:27
MT Newswires
04/06 05:41
Yahoo
04/04 12:02
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 06/01/2022* | -- | Results | Q4 2022 | -- | 1.80 | -- | |
| 02/03/2022 | -- | Results | Q3 2022 | 2.35 | 1.32 | 77.35% | |
| 11/04/2021 | -- | Results | Q2 2022 | 1.60 | 1.07 | 50.40% | |
| 08/05/2021 | -- | Results | Q1 2022 | 1.51 | 1.02 | 48.59% | |
| 06/01/2021 | -- | Results | Q4 2021 | 1.74 | 1.07 | 63.14% | |
| 02/03/2021 | -- | Results | Q3 2021 | 0.43 | 1.04 | -58.23% | |
| 11/05/2020 | -- | Results | Q2 2021 | 1.91 | 1.07 | 78.77% | |
| 08/06/2020 | -- | Results | Q1 2021 | 1.67 | 1.78 | -6.18% |
*Estimated Date/Time
Earnings
Profile
Edit
| Mesa Laboratories Inc provides control products and services. Its Instruments division manufactures quality-control instruments and disposable products for the pharmaceutical, food and beverage, medical device, industrial hygiene, air sampling, and semiconductor industries. The Sterilization and disinfection control division provides testing services, as well as biological and chemical indicators used to assess the efficacy of sterilization and disinfection processes. The Continuous monitoring division designs, develops and markets systems used to monitor environmental parameters, such as temperature and humidity. The biopharmaceutical development division develops and manufactures automated systems for protein analysis. The company generates most of the revenue from the United States. |
| URL | https://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 01, 2022 (est.) |
| Last Earnings Release | Feb. 03, 2022 |
| Next Ex-Dividend Date | May. 27, 2022 |
| Last Ex-Dividend Date | Feb. 25, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.64 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.2278 |
| Yield to Sector | 0.2324 |
| Yield to Industry | 0.3037 |
| Last Dividend Amt. | 0.16 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Feb. 25, 2022 |
| Yield (TTM) | 0.30% |
| Forward Yield | 0.30% |
| Payout Ratio | 43.82% |
| Cash Payout Ratio | 8.56% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 20, 2022.
Fundamentals
| Revenue (TTM) | 163.42M |
| Total Expenses (TTM) | 154.22M |
| Net Income (TTM) | 7.575M |
| Total Assets (Quarterly) | 721.71M |
| Total Liabilities (Quarterly) | 325.38M |
| Shareholders Equity (Quarterly) | 396.33M |
| Cash from Operations (TTM) | 43.44M |
| Cash from Investing (TTM) | -305.48M |
| Cash from Financing (TTM) | 61.58M |
Ratings
Profile
Edit
| Mesa Laboratories Inc provides control products and services. Its Instruments division manufactures quality-control instruments and disposable products for the pharmaceutical, food and beverage, medical device, industrial hygiene, air sampling, and semiconductor industries. The Sterilization and disinfection control division provides testing services, as well as biological and chemical indicators used to assess the efficacy of sterilization and disinfection processes. The Continuous monitoring division designs, develops and markets systems used to monitor environmental parameters, such as temperature and humidity. The biopharmaceutical development division develops and manufactures automated systems for protein analysis. The company generates most of the revenue from the United States. |
| URL | https://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 01, 2022 (est.) |
| Last Earnings Release | Feb. 03, 2022 |
| Next Ex-Dividend Date | May. 27, 2022 |
| Last Ex-Dividend Date | Feb. 25, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| MLAB Tweets |